It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its ...
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, according to the filing. In its own press release, Sage called the ...
Sage Therapeutics SAGE announced that its partner ... Inc. GSK plc GSK announced an agreement to acquire clinical-stage private biotech IDRx, which makes precision therapeutics for treating ...
Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results